Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA dates

• Praxis Precision Medicines highlighted four late-stage CNS programs, citing portfolio peak sales potential above USD 20 billion.
• Ulixacaltamide for essential tremor is under FDA review with a January 2027 PDUFA date; the company cited two positive Phase 3 studies.
• Relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathies has an FDA target action date of December 27, 2026.
• The company expects a Q4 2026 topline readout from EMERALD, a Phase 3 study of relutrigine in phenotypic DEEs with about 200 patients.
• Praxis also cited cash runway into 2028 while preparing for a potential ulixacaltamide launch in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.